|5th January 2021||Richard Jr Mejia||9,423||Grant/award etc.||$0.00|
|5th January 2021||Martin J Colombatto||10,000||Grant/award etc.||$0.00|
|5th January 2021||William R Enquist||7,243||Grant/award etc.||$0.00|
|5th January 2021||Mark E Saad||8,227||Grant/award etc.||$0.00|
|20th November 2020||Daniel Horwood||200||Grant/award etc.||$5.43||$1,086.30|
|20th November 2020||Jeffrey J Kraws||200||Grant/award etc.||$5.43||$1,086.30|
|20th November 2020||Andrew C. Jackson||200||Grant/award etc.||$5.43||$1,086.30|
|19th November 2020||Richard Jr Mejia||1,000||Open or private purchase||$5.82||$5,820.00|
|19th November 2020||William R Enquist||5,263||Open or private purchase||$5.82||$30,621.71|
|19th November 2020||Martin J Colombatto||8,700||Open or private purchase||$5.78||$50,279.04|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Ra Medical Systems, Inc. engages in the design, development, and commercialization of excimer lasers. Its product, Pharos, is used for the treatment of difficult-to-treat, chronic diseases including psoriasis and vitiligo. It operates through the Dermatology and Vascular business segments.